Author Voices: Peter Johnson, MA, MD, FRCP
443 views · Published 14 July 2016 · 4:01 · Indexed 20 October 2026
Channel: American Society of Hematology · 2016 · Nonprofits & Activism
There is an emerging interest in applying quantitative metrics using positron emission tomography (PET) to predict prognosis in malignant non-Hodgkin lymphoma (NHL). Primary mediastinal B-cell lymphoma (PMBCL) is a clinicopathological entity of aggressive NHL. Dr. Johnson talks about his team’s Blood paper, “Utility of baseline 18FDG PET/CT functional parameters in defining prognosis of primary mediastinal (thymic) large B-cell lymphoma” which presents a new prognostic imaging biomarker of tumor metabolism based on pretreatment [18F]fluorodeoxyglucose (FDG)-PET/computed tomography, which they evaluated in a prospective study of patients with PMBCL. These new data open an exciting perspective. It might be possible to use baseline quantitative FDG-PET to define a risk-adapted therapeutic strategy in PMBCL as early as at diagnosis. http://www.bloodjournal.org/content/126/8/950
More from this channel
-
1:52
Ron Reagan Accepts ASH Award - Stem Cell Research
-
4:25
Sen. Jim Talent's Work on Sickle Cell Disease Legislation
-
3:56
ASH and the Reagans Support Stem Cell Research
-
5:42
The American Society of Hematology Celebrates its 50th Anniversary
-
5:57
David Nathan Receives 2011 Wallace H. Coulter Award for Lifetime Achievement in Hematology
-
5:17
James George Receives 2012 Wallace H. Coulter Award for Lifetime Achievement in Hematology
-
2:21
Congress: Protect NIH funding
-
2:21
Act Now: Tell Congress to Stop Further Cuts to Research Funding